A Multicenter, Randomized, Open, Phase 2 Trial of SHR-1210 Plus Apatinib Versus Doxorubicin (ADM) Plus Ifosfamide (IFO) in Patients With Soft Tissue Sarcoma
Latest Information Update: 05 Mar 2024
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Doxorubicin; Ifosfamide
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 27 Feb 2024 Dose of Apatinib is increased from 375 mg to 500 mg.
- 15 Jun 2023 Status changed to discontinued.
- 07 Dec 2022 Status changed from recruiting to completed.